Przemyslaw Twardowski

Dr. Przemyslaw Twardowski


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Journal of Urology
Verified
Journal Article
Open access
AJAshesh B. Jani
Ashesh B. Jani
GRGregory C Ravizzini
Gregory C Ravizzini
BGBenjamin A. Gartrell
Benjamin A. Gartrell
BSBarry A. Siegel
Barry A. Siegel
PTPrzemyslaw Twardowski
Przemyslaw Twardowski
KZKatherine Zukotynski
Katherine Zukotynski
SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid (rh) 18F-rhPSMA-7.3, a novel high-affinity PET radiopharmaceutical. Men with prostate cancer recurrence underwent PET/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the co-primary endpoints (verified detection rate [VDR] and combined region-level positive predictive value [crPPV]), 3 blinded, independent central readers evaluated the scans. VDR is equivalent to the overall detection rate (DR) x PPV. Standard of Truth (SoT) was established for each patient using histopathology or confirmatory imaging. Statistical thresholds (lower bounds of the confidence intervals) of 36.5% and 62.5% were prespecified for VDR and crPPV, respectively. Additional endpoints included DR, VDR and crPPV in patients with histopathology SoT, and safety. The overall 18F-rhPSMA-7.3 DR among all 389 patients with an evaluable scan was 83% (majority read). Among the 366 patients (median PSA, 1.27 ng/mL) for whom a SOT (histopathology [n=69]/confirmatory imaging only [n=297]) was available, VDR ranged from 51% (95%CI, 46.1-56.6) to 54% (95%, 48.8-59.3), exceeding the prespecified statistical threshold. crPPV ranged from 46% (95%CI, 42.0-50.3%) to 60% (95%CI, 55.1-65.5%) across the readers, not meeting the threshold. In the subset of patients with histopathology SoT, the VDR and crPPV were both above the prespecified thresholds (majority read, 81% [95%CI, 69.9-89.6] and 72% [95%CI, 62.5-80.7], respectively). No significant safety concerns were identified. 18F-rhPSMA-7.3 offers a clinically meaningful VDR for localization of recurrent prostate cancer. Despite missing the co-primary endpoint of crPPV, the totality of the data support the potential clinical utility of 18F-rhPSMA-7.3.

1 January 2019 in Cancer Treatment and Research Communications
Verified
Journal Article
Closed access
PTPrzemyslaw Twardowski
Przemyslaw Twardowski
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
SPSumanta K. Pal
Sumanta K. Pal
BMBenjamin L. Maughan
Benjamin L. Maughan
PFPaul Henry Frankel
Paul Henry Frankel
NANeeraj Agarwal
Neeraj Agarwal

27 November 2017 in Kidney Cancer
Verified
Journal Article
Open access
PDF file
PTPrzemyslaw Twardowski
Przemyslaw Twardowski
CTCatherine M. Tangen
Catherine M. Tangen
XWXiwei Wu
Xiwei Wu
MPMelissa R. Plets
Melissa R. Plets
EPElizabeth R. Plimack
Elizabeth R. Plimack
PLPrimo Lara
Primo Lara
Background: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or in combination with EGFR inhibitor erlotinib was conducted in patients with pRCC. Methods: Patients with advanced pRCC and 0-1 prior systemic therapy were randomly assigned to tivantinib 360 mg BID (Arm 1) or tivantinib 360 mg BID plus erlotinib 150 mg daily (Arm 2). Target max accrual was 70 patients (35 per arm) with interim analysis planned after enrollment of 20 patients per arm. Results: Six % of patients had type 1 pRCC, 42% had type 2, and 52% had no subtype assigned. The study was closed after the first stage when both arms yielded RR of 0%. Median progression free survival (PFS) was 2.0 and 3.9 months, and OS was 10.3 and 11.3 months in Arms 1 and 2 respectively. Treatment was well tolerated. Exome of tumor tissue from 16 patients were successfully sequenced using Agilent SureSelect probes. Only 1 of 16 samples harbored MET mutation. Other mutations associated primarily with type 2 pRCC were noted and included CDKN2A, PBRM1, SETD2, KDM6A, FAT1 and NF2. Conclusions: Tivantinib - either alone or in combination with erlotinib has no clinical activity in patients with advanced pRCC. The S1107 cohort had a low proportion of patients with MET alterations. MET remains a reasonable therapeutic target in pRCC, but selection of patient subsets exhibiting MET activation may be required to better benefit from therapy with MET inhibitors.

30 May 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SGShuchi Gulati
Shuchi Gulati
PBPedro Barata
Pedro Barata
AEAndrew Elliott
Andrew Elliott
MBMehmet Bilen
Mehmet Bilen
EBEarle F. Burgess
Earle F. Burgess
RMRana R. McKay
Rana R. McKay
BACKGROUND: Metastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood. Renal cell carcinoma (RCC) is known to have distinct sites of metastases, with lung, bone, liver, and lymph nodes being more common than brain, gastrointestinal tract, and endocrine glands. Previous studies have shown varying clinical behavior and prognosis associated with the site of metastatic spread; however, little is known about the molecular underpinnings that contribute to the differential outcomes observed by the site of metastasis. METHODS: We analyzed primary renal tumors and tumors derived from metastatic sites to comprehensively characterize genomic and transcriptomic features of tumor cells as well as to evaluate the tumor microenvironment at both sites. RESULTS: We included a total of 657 tumor samples (340 from the primary site [kidney] and 317 from various sites of metastasis). We show distinct genomic alterations, transcriptomic signatures, and immune and stromal tumor microenvironments across metastatic sites in a large cohort of patients with RCC. CONCLUSION: We demonstrate significant heterogeneity among primary tumors and metastatic sites and elucidate the complex interplay between tumor cells and the extrinsic tumor microenvironment that is vital for developing effective anticancer therapies.

23 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Xiaoqiang WangXiaoqiang Wang
Xiaoqiang Wang
YCYin Chan
Yin Chan
KWKelly Wong
Kelly Wong
RYRyohei Yoshitake
Ryohei Yoshitake
DSDavid Sadava
David Sadava
SCShiuan Chen
Shiuan Chen
Cancer progression and mortality remain challenging because of current obstacles and limitations in cancer treatment. Continuous efforts are being made to explore complementary and alternative approaches to alleviate the suffering of cancer patients. Epidemiological and nutritional studies have indicated that consuming botanical foods is linked to a lower risk of cancer incidence and/or improved cancer prognosis after diagnosis. From these observations, a variety of preclinical and clinical studies have been carried out to evaluate the potential of botanical food products as anticancer medicines. Unfortunately, many investigations have been poorly designed, and encouraging preclinical results have not been translated into clinical success. Botanical products contain a wide variety of chemicals, making them more difficult to study than traditional drugs. In this review, with the consideration of the regulatory framework of the USFDA, we share our collective experiences and lessons learned from 20 years of defining anticancer foods, focusing on the critical aspects of preclinical studies that are required for an IND application, as well as the checkpoints needed for early-phase clinical trials. We recommend a developmental pipeline that is based on mechanisms and clinical considerations.

7 May 2026 in Current Problems in Cancer
Verified
Journal Article
Closed access
ADAnishka D'Souza
Anishka D'Souza
SGSusan G Groshen
Susan G Groshen
DTDenice Tsao-Wei
Denice Tsao-Wei
NRNora H Ruel
Nora H Ruel
TDTanya Barauskas Dorff
Tanya Barauskas Dorff
ENEdward M Newman
Edward M Newman